All In Biotech

Free tool

FAERS Monitor: Orkambi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211358 or its brand name (Orkambi, Ivacaftor, Lumacaftor). Reports on generic versions are filed under their own applications.

Reports

8,538

Serious

5,384

63% of reports

Hospitalization

4,461

Death reported

158

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infective pulmonary exacerbation of cystic fibrosis1,462
  • hospitalisation888
  • dyspnoea559
  • pulmonary function test decreased397
  • cough395
  • infection370
  • chest discomfort344
  • cystic fibrosis328
  • pneumonia269
  • malaise225
  • nasopharyngitis202
  • fatigue200
  • diarrhoea195
  • respiration abnormal191
  • pyrexia187

Reports by year received

View as table
YearReports
2015613
20161,493
20171,499
20181,638
20191,989
2020728
2021169
2022121
2023120
202469
202547
202652

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,621 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal1,462904.1854.8964,532
pulmonary function test decreasedSignal397245.6222.087,733
cystic fibrosisSignal328155.1139.047,103
respiration abnormalSignal19170.260.912,602
hospitalisationSignal88814.313.411,000
chest discomfortSignal3448.37.52,205
infectionSignal3706.35.71,656
coughSignal3953.53.2702
nasopharyngitisSignal2022.72.4216
dyspnoeaSignal5592.42.2483
pneumoniaSignal2692.01.8145
pyrexia1871.31.215
malaise2251.31.112
diarrhoea1950.70.617
fatigue2000.60.644

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.